BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Kidney Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Kidney Diseas
 e\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122401-897@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:MT1013: Phase 3 readout est. (NCT07122401)
DESCRIPTION:MT1013\, phase 3\, Chronic Kidney Disease.\nStudy: Study of MT1
 013 for the Treatment of Patients With Secondary Hyperparathyroidism\nEsti
 mated primary completion: 26 November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mt1013#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07122401
URL:https://assetmemo.bio/drug/mt1013#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0722291
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: A Phase IIb Study to Evaluate the Effect of Dapagliflozin i
 n Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in P
 articipants With Chronic Kidney Disease and High Blood Pressure.\nEstimate
 d primary completion: 10 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07222917
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-525@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Baxfendy (Baxdrostat): Phase 2 readout est. (NCT07222917)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 2\, Hypertension.\nStudy: A Phase
  IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Bax
 drostat Compared With Baxdrostat on Albuminuria in Participants With Chron
 ic Kidney Disease and High Blood Pressure.\nEstimated primary completion: 
 10 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bax
 drostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07222917
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05507892-307@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT05507892)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Type 2 Diabetes.\nStudy: R
 enal Mechanism of SGLT2 Inhibition\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/canaglifloz
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5507892
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786443-308@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT05786443)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Chronic Kidney Disease.\n
 Study: Safety and Efficacy of Empagliflozin in Hemodialysis\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05786443
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578078-608@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 06578078)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: A Clinical Trial to Define the Best Strategy for the
  Management of Heart Failure in Elderly Patients\nEstimated primary comple
 tion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sodium-zirconium-cyclosilicate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06578078
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06155604-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0615560
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Ki
 dney Disease\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06155604
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06531824-369@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06531824)
DESCRIPTION:Vicadrostat\, phase 3\, Chronic Kidney Disease.\nStudy: EASi-KI
 DNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combin
 ation With Empagliflozin)\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06531824
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819826-945@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SC0062: Phase 3 readout est. (NCT06819826)
DESCRIPTION:SC0062\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of S
 C0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sc0062#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06819826
URL:https://assetmemo.bio/drug/sc0062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678203-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 1/2 readout est. (NCT07678
 203)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 1/2\, Chronic Kidney 
 Disease.\nStudy: Dapagliflozin to Reduce the Decline in Renal Function in 
 Patients Newly Diagnosed With Lupus Nephritis\nEstimated primary completio
 n: 28 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 apagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07678203
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087835-536@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Zibotentan + Dapagliflozin: Phase 3 readout est. (NCT06087835)
DESCRIPTION:Zibotentan + Dapagliflozin\, phase 3\, Chronic Kidney Disease.\
 nStudy: Study to Investigate Efficacy\, Safety\, and Tolerability of Zibot
 entan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic
  Kidney Disease and High Proteinuria (ZENITH High Proteinuria)\nEstimated 
 primary completion: 18 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06087835
URL:https://assetmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494409-899@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:AND017: Phase 3 readout est. (NCT07494409)
DESCRIPTION:AND017\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of A
 ND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney
  Disease (DD-CKD) Patients With Anemia\nEstimated primary completion: 20 F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/and017#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749
 4409
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487727-899@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:AND017: Phase 3 readout est. (NCT07487727)
DESCRIPTION:AND017\, phase 3\, Chronic Kidney Disease.\nStudy: A Study of A
 ND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-D
 ialysis-Dependent Chronic Kidney Disease (NDD-CKD)\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /and017#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07487727
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565701-874@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Vafseo (Vadadustat): Phase 3 readout est. (NCT07565701)
DESCRIPTION:Vafseo (Vadadustat)\, phase 3\, Chronic Kidney Disease.\nStudy:
  Safety and Efficacy of a Phased Transition From Epogen to Three Times Wee
 kly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-C
 enter Hemodialysis\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vadadustat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07565701
URL:https://assetmemo.bio/drug/vadadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05196035-661@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05196035)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Well the Study Treatment Finerenone Wor
 ks\, How Safe it is\, How it Moves Into\, Through\, and Out of the Body\, 
 and the Effects it Has on the Body When Taken With an ACE Inhibitor or Ang
 iotensin Receptor Blocker in Children With Chronic Kidney Disease and Prot
 einuria\nEstimated primary completion: 10 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05196035
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107945-308@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07107945)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps 
 Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)\
 nEstimated primary completion: 16 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07107945
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06147232-314@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT06147232)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Chronic Kidney Disease.\nStu
 dy: Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabet
 es With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding 
 Kidney hypOxia\nEstimated primary completion: May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06147232
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0759886
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD 
 With Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-661@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07598864)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With 
 Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05715814-308@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05715814)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis\nE
 stimated primary completion: 1 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05715814
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05822609-114@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT05822609)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2\, Chronic Kidney Disease.\nStud
 y: Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05822609
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268638-940@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Praliciguat: Phase 2 readout est. (NCT07268638)
DESCRIPTION:Praliciguat\, phase 2\, Chronic Kidney Disease.\nStudy: A Study
  of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (F
 SGS)\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/praliciguat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07268638
URL:https://assetmemo.bio/drug/praliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962098-372@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Isuzinaxib: Phase 2 readout est. (NCT06962098)
DESCRIPTION:Isuzinaxib\, phase 2\, Chronic Kidney Disease.\nStudy: Efficacy
  and Safety Study of Isuzinaxib in Subjects With DKD\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/isuzinaxib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06962098
URL:https://assetmemo.bio/drug/isuzinaxib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969329-878@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03969329)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Secondary Hyperparathyroid
 ism.\nStudy: A Phase 3 Study of Etelcalcetide in Children With Secondary H
 yperparathyroidism Receiving Hemodialysis\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etelcalc
 etide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03969329
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374291-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0537429
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapaglifloz
 in on Renal and Cardiovascular Outcomes in Patients With Severe CKD\nEstim
 ated primary completion: July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05374291
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578533-608@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 06578533)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: Keeping RAASi Treatment With Optimal Potassium Contr
 ol\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06578533
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483074-308@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06483074)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Chronic Kidney Disease.\n
 Study: Empagliflozin on Residual Kidney Function in Incident Peritoneal Di
 alysis Patients\nEstimated primary completion: 31 July 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06483074
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852938-909@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Zigakibart: Phase 3 readout est. (NCT05852938)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: A Study 
 of Zigakibart in Adults With IgA Nephropathy\nEstimated primary completion
 : 10 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zig
 akibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05852938
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201467-546@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:KN060: Phase 1/2 readout est. (NCT07201467)
DESCRIPTION:KN060\, phase 1/2\, Chronic Kidney Disease.\nStudy: To Assess t
 he Safety\, Tolerability\, Pharmacokinetics and Pharmacodynamics of KN060 
 in ESRD Dialysis Patients\nEstimated primary completion: 15 August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/kn060#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07201467
URL:https://assetmemo.bio/drug/kn060#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944016-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0594401
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney
  Disease in Adolescents and Young Adult Patients\nEstimated primary comple
 tion: September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05944016
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494045-881@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rayaldee (Extended-release calcifediol): Phase 2 readout est. (NCT0
 7494045)
DESCRIPTION:Rayaldee (Extended-release calcifediol)\, phase 2\, Chronic Kid
 ney Disease.\nStudy: Pharmacokinetics\, Pharmacodynamics\, Safety and Tole
 rability Evaluation of CTAP101 Extended-release Capsules in Pediatric Part
 icipants\nEstimated primary completion: October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/extended-release-calcifediol#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07494045
URL:https://assetmemo.bio/drug/extended-release-calcifediol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647133-944@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:SAL0140: Phase 2 readout est. (NCT07647133)
DESCRIPTION:SAL0140\, phase 2\, Chronic Kidney Disease.\nStudy: A Phase II 
 Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Pat
 ients With Chronic Kidney Disease\nEstimated primary completion: 8 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sal0140#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07647133
URL:https://assetmemo.bio/drug/sal0140#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970172-873@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT05970172)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chr
 onic Kidney Disease\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/roxadustat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05970172
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323095-921@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lingdolinurad: Phase 2 readout est. (NCT07323095)
DESCRIPTION:Lingdolinurad\, phase 2\, Chronic Kidney Disease.\nStudy: Evalu
 ate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Dis
 ease and Hyperuricaemia\nEstimated primary completion: 31 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lingdolinurad#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07323095
URL:https://assetmemo.bio/drug/lingdolinurad#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555054-931@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:HS-10390: Phase 2 readout est. (NCT07555054)
DESCRIPTION:HS-10390\, phase 2\, Chronic Kidney Disease.\nStudy: A Study of
  the Effect and Safety of HS-10390 in the Treatment of Participants With C
 hronic Kidney Disease\nEstimated primary completion: 11 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/hs-10390#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07555054
URL:https://assetmemo.bio/drug/hs-10390#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181135-661@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07181135)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic 
 Kidney Disease Not Using Renin-angiotensin-system Inhibitors\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07181135
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355296-902@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280120
DTEND;VALUE=DATE:20280121
SUMMARY:Apecotrep: Phase 2 readout est. (NCT07355296)
DESCRIPTION:Apecotrep\, phase 2\, Chronic Kidney Disease.\nStudy: PODOMOUNT
 -Basket\, a Study to Test Whether BI 764198 Helps Adults and Adolescents W
 ith Different Types of Kidney Disease\nEstimated primary completion: 20 Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apecotrep
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 55296
URL:https://assetmemo.bio/drug/apecotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304817-308@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07304817)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Co
 mparative Study on the Mode of Action of Vicadrostat and Spironolactone on
  Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)\nEstimated pr
 imary completion: February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07304817
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304817-369@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Vicadrostat: Phase 2 readout est. (NCT07304817)
DESCRIPTION:Vicadrostat\, phase 2\, Heart Failure.\nStudy: Comparative Stud
 y on the Mode of Action of Vicadrostat and Spironolactone on Protein Profi
 les and Renal Hemodynamic Effects (COMPARE-VS)\nEstimated primary completi
 on: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vi
 cadrostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07304817
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0626887
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Investigate the Efficacy and Safety of
  Baxdrostat in Combination With Dapagliflozin on CKD Progression in Partic
 ipants With CKD and High Blood Pressure.\nEstimated primary completion: 24
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268873
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-525@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06268873)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Study to Investigate the Efficacy and Safety of Baxdrostat in Combina
 tion With Dapagliflozin on CKD Progression in Participants With CKD and Hi
 gh Blood Pressure.\nEstimated primary completion: 24 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06268873
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913647-307@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT06913647)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Chronic Kidney Disease.\nS
 tudy: Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on
  Peritoneal Dialysis\nEstimated primary completion: 28 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/canagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06913647
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676579-955@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tavneos (Avacopan): Phase 2 readout est. (NCT06676579)
DESCRIPTION:Tavneos (Avacopan)\, phase 2\, Chronic Kidney Disease.\nStudy: 
 Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)\nEstimated prim
 ary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06676579
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182839-307@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT06182839)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Chronic Kidney Disease.\nS
 tudy: Canagliflozin in Advanced Renal Disease With MRI Endpoints\nEstimate
 d primary completion: 30 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/canagliflozin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06182839
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-909@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Zigakibart: Phase 3 readout est. (NCT04573478)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Atrasent
 an in Patients With IgA Nephropathy\nEstimated primary completion: 14 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zigakibart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045734
 78
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05312879-913@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280602
DTEND;VALUE=DATE:20280603
SUMMARY:Inaxaplin: Phase 2/3 readout est. (NCT05312879)
DESCRIPTION:Inaxaplin\, phase 2/3\, Chronic Kidney Disease.\nStudy: Phase 2
 /3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1
 -Mediated Proteinuric Kidney Disease\nEstimated primary completion: 2 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inaxaplin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05312879
URL:https://assetmemo.bio/drug/inaxaplin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662135-148@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280713
DTEND;VALUE=DATE:20280714
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662135)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Functio
 n on Background Dapagliflozin\nEstimated primary completion: 13 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07662135
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05457283-661@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05457283)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Safe the Study Treatment Finerenone is 
 in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor 
 Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Ye
 ars of Age With Chronic Kidney Disease and Proteinuria\nEstimated primary 
 completion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05457283
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642050-901@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:BHV-1400: Phase 3 readout est. (NCT07642050)
DESCRIPTION:BHV-1400\, phase 3\, Chronic Kidney Disease.\nStudy: A Study to
  Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropath
 y\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bhv-1400#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07642050
URL:https://assetmemo.bio/drug/bhv-1400#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963827-3188@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280907
DTEND;VALUE=DATE:20280908
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06963827)
DESCRIPTION:Mezagitamab\, phase 3\, Chronic Kidney Disease.\nStudy: A Study
  of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy\nEs
 timated primary completion: 7 September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mezagitamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963827
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271186-353@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:ALN-ANG3: Phase 2 readout est. (NCT07271186)
DESCRIPTION:ALN-ANG3\, phase 2\, Chronic Kidney Disease.\nStudy: Study to A
 ssess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney D
 isease\nEstimated primary completion: 13 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aln-ang3#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07271186
URL:https://assetmemo.bio/drug/aln-ang3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217302-314@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06217302)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Heart Failure.\nStudy: Sotag
 liflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes a
 nd Diabetic Kidney Disease\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sotagliflozin-inpefa#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06217
 302
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220083-902@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Apecotrep: Phase 3 readout est. (NCT07220083)
DESCRIPTION:Apecotrep\, phase 3\, Chronic Kidney Disease.\nStudy: A Study t
 o Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Conditi
 on Called Focal Segmental Glomerulosclerosis (FSGS)\nEstimated primary com
 pletion: 27 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apecotrep#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07220083
URL:https://assetmemo.bio/drug/apecotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072326-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0607232
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: dApagliflozin SC0062 and Prevention of Renal Injury\; a Ran
 domized Evaluation\nEstimated primary completion: January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06072326
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072326-945@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:SC0062: Phase 2 readout est. (NCT06072326)
DESCRIPTION:SC0062\, phase 2\, Chronic Kidney Disease.\nStudy: dApagliflozi
 n SC0062 and Prevention of Renal Injury\; a Randomized Evaluation\nEstimat
 ed primary completion: January 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sc0062#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06072326
URL:https://assetmemo.bio/drug/sc0062#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025629-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0702562
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Dapagliflozin for Cardio-renal Protection After ICU Discharge\nEstim
 ated primary completion: 15 January 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07025629
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03633708-878@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03633708)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Chronic Kidney Disease.\nS
 tudy: A Trial of Etelcalcetide in Pediatric Participants With Secondary Hy
 perparathyroidism and Chronic Kidney Disease on Hemodialysis\nEstimated pr
 imary completion: 31 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/etelcalcetide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03633708
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325201-314@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT07325201)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Chronic Kidney Disease.\nStu
 dy: Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Usin
 g Dual Continuous Ketone and Glucose Monitoring.\nEstimated primary comple
 tion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sotagliflozin-inpefa#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07325201
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383390-118@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:retatrutide: Phase 3 readout est. (NCT06383390)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: The Effect of Retatrut
 ide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults L
 iving With Obesity (TRIUMPH-Outcomes)\nEstimated primary completion: Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retatrutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 83390
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060417-308@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07060417)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Chronic Kidney Disease.\n
 Study: Vascular Effects of SGLT2i in Non-diabetic CKD\nEstimated primary c
 ompletion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07060417
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06593392-883@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Korsuva (Difelikefalin): Phase 2 readout est. (NCT06593392)
DESCRIPTION:Korsuva (Difelikefalin)\, phase 2\, Chronic Kidney Disease.\nSt
 udy: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialy
 sis With Moderate-to-Severe Pruritus\nEstimated primary completion: 15 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/difelikefal
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6593392
URL:https://assetmemo.bio/drug/difelikefalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099770-917@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Neo-Kidney Augment / REACT (Rilparencel): Phase 3 readout est. (NCT
 05099770)
DESCRIPTION:Neo-Kidney Augment / REACT (Rilparencel)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: Proact: A Study of REACT in Subjects With Type 2 Dia
 betes Mellitus and Chronic Kidney Disease\nEstimated primary completion: D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilpare
 ncel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05099770
URL:https://assetmemo.bio/drug/rilparencel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0674272
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Renal Outcomes and Cardiovascular Mortality Stu
 dy to Investigate the Efficacy and Safety of Baxdrostat in Combination Wit
 h Dapagliflozin in Participants With Chronic Kidney Disease and High Blood
  Pressure\nEstimated primary completion: 18 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-525@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06742723)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Renal Outcomes and Cardiovascular Mortality Study to Investigate the 
 Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Par
 ticipants With Chronic Kidney Disease and High Blood Pressure\nEstimated p
 rimary completion: 18 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/baxdrostat#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594145-314@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT07594145)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Heart Failure.\nStudy: Preci
 sion T1D Platform - New Therapies for Cardio-Renal Complications\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07594145
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594145-661@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT07594145)
DESCRIPTION:Kerendia (Finerenone)\, phase 2\, Heart Failure.\nStudy: Precis
 ion T1D Platform - New Therapies for Cardio-Renal Complications\nEstimated
  primary completion: 31 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07594145
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058585-114@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT06058585)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Chronic Kidney Disease.\nStud
 y: The Chronic Kidney Disease Adaptive Platform Trial Investigating Variou
 s Agents for Therapeutic Effect\nEstimated primary completion: 31 December
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-oz
 empic#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06058585
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058585-661@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06058585)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: The Chronic Kidney Disease Adaptive Platform Trial Investigating Variou
 s Agents for Therapeutic Effect\nEstimated primary completion: 31 December
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0605858
 5
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07419828-452@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:HRS-1780: Phase 3 readout est. (NCT07419828)
DESCRIPTION:HRS-1780\, phase 3\, Chronic Kidney Disease.\nStudy: A Phase II
 I Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment o
 f Patients With Chronic Kidney Disease\nEstimated primary completion: Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-1780#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07419828
URL:https://assetmemo.bio/drug/hrs-1780#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624305-306@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0762430
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Evaluate the Effect of Balcinrenone/Da
 pagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)\nEstimated 
 primary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07624305
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624305-594@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Balcinrenone: Phase 3 readout est. (NCT07624305)
DESCRIPTION:Balcinrenone\, phase 3\, Chronic Kidney Disease.\nStudy: A Phas
 e III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With CKD Stage 3b and 4 (BalanceD-CKD)\nEstimated primary completion: 1
  July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/balcinren
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07624305
URL:https://assetmemo.bio/drug/balcinrenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134335-199@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:UBT251: Phase 2 readout est. (NCT07134335)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: UBT251 Injection Phase II C
 linical Study (CKD)\nEstimated primary completion: 11 July 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07134335
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146906-909@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20300712
DTEND;VALUE=DATE:20300713
SUMMARY:Zigakibart: Phase 2 readout est. (NCT07146906)
DESCRIPTION:Zigakibart\, phase 2\, Chronic Kidney Disease.\nStudy: A Study 
 to Assess the Effects of Zigakibart on IgA Nephropathy.\nEstimated primary
  completion: 12 July 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zigakibart#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07146906
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753993-148@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20301004
DTEND;VALUE=DATE:20301005
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07753993)
DESCRIPTION:elecoglipron\, phase 3\, Chronic Kidney Disease.\nStudy: A Stud
 y to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult
  Participants With Chronic Kidney Disease.\nEstimated primary completion: 
 4 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eleco
 glipron#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07753993
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557462-887@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20301204
DTEND;VALUE=DATE:20301205
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04557462)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Rollover Extension Program (REP) to Evaluate the Long-term Safety and 
 Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary I
 gA Nephropathy\nEstimated primary completion: 4 December 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04557462
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625774-186@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07625774)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Chronic Kidney Disease.\nStu
 dy: Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS
 -7535 Evaluated in Participants With Chronic Kidney Disease\nEstimated pri
 mary completion: May 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07625774
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858319-909@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20310625
DTEND;VALUE=DATE:20310626
SUMMARY:Zigakibart: Phase 3 readout est. (NCT06858319)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Open-lab
 el Extension Study of Zigakibart in Adults With IgA Nephropathy.\nEstimate
 d primary completion: 25 June 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zigakibart#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06858319
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04580420-911@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Rivfloza (Nedosiran): Phase 2 readout est. (NCT04580420)
DESCRIPTION:Rivfloza (Nedosiran)\, phase 2\, Chronic Kidney Disease.\nStudy
 : Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD\nEstimated p
 rimary completion: 30 December 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nedosiran#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04580420
URL:https://assetmemo.bio/drug/nedosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890584-905@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20320222
DTEND;VALUE=DATE:20320223
SUMMARY:UPASITA (Upacicalcet): Phase 3 readout est. (NCT07890584)
DESCRIPTION:UPASITA (Upacicalcet)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study of PLS240 in Pediatric Participants With Secondary Hyperparathy
 roidism and Chronic Kidney Disease on Hemodialysis\nEstimated primary comp
 letion: 22 February 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/upacicalcet#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07890584
URL:https://assetmemo.bio/drug/upacicalcet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
